Operaciones Angion Biomedica Corp. - ANGN CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.0644 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024874% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.002651% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 0.4848 |
Abrir* | 0.5402 |
Cambio de 1 año* | -72.58% |
Rango del día* | 0.5014 - 0.5471 |
Rango de 52 semanas | 0.46-2.37 |
Volumen medio (10 días) | 17.70K |
Volumen medio (3 meses) | 1.40M |
Capitalización de mercado | 15.32M |
Ratio P/E | -100.00K |
Acciones en circulación | 30.11M |
Ingresos | 2.30M |
EPS | -1.29 |
Dividendo (Rendimiento %) | N/A |
Beta | -100.00K |
Próxima fecha de resultados | Mar 31, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 30, 2023 | 0.4848 | 0.0072 | 1.51% | 0.4776 | 0.5475 | 0.4688 |
Mar 29, 2023 | 0.4887 | 0.0197 | 4.20% | 0.4690 | 0.4887 | 0.4688 |
Mar 28, 2023 | 0.4642 | -0.0146 | -3.05% | 0.4788 | 0.4788 | 0.4642 |
Mar 27, 2023 | 0.4799 | 0.0009 | 0.19% | 0.4790 | 0.5252 | 0.4786 |
Mar 24, 2023 | 0.4885 | -0.0390 | -7.39% | 0.5275 | 0.5276 | 0.4884 |
Mar 23, 2023 | 0.5307 | 0.0028 | 0.53% | 0.5279 | 0.5374 | 0.5238 |
Mar 22, 2023 | 0.4887 | 0.0096 | 2.00% | 0.4791 | 0.4890 | 0.4791 |
Mar 21, 2023 | 0.4789 | 0.0248 | 5.46% | 0.4541 | 0.4791 | 0.4493 |
Mar 20, 2023 | 0.4881 | 0.0001 | 0.02% | 0.4880 | 0.4986 | 0.4739 |
Mar 17, 2023 | 0.4887 | -0.0490 | -9.11% | 0.5377 | 0.5378 | 0.4823 |
Mar 16, 2023 | 0.5081 | 0.0198 | 4.05% | 0.4883 | 0.5695 | 0.4883 |
Mar 15, 2023 | 0.4930 | -0.0542 | -9.90% | 0.5472 | 0.5671 | 0.4888 |
Mar 14, 2023 | 0.5372 | -0.0196 | -3.52% | 0.5568 | 0.5963 | 0.5372 |
Mar 13, 2023 | 0.5377 | -0.0240 | -4.27% | 0.5617 | 0.5621 | 0.5208 |
Mar 10, 2023 | 0.5132 | -0.0641 | -11.10% | 0.5773 | 0.5778 | 0.5054 |
Mar 9, 2023 | 0.5568 | -0.0604 | -9.79% | 0.6172 | 0.6256 | 0.5375 |
Mar 8, 2023 | 0.5960 | 0.0078 | 1.33% | 0.5882 | 0.6158 | 0.5882 |
Mar 7, 2023 | 0.6060 | -0.0094 | -1.53% | 0.6154 | 0.6155 | 0.6056 |
Mar 6, 2023 | 0.6256 | -0.0208 | -3.22% | 0.6464 | 0.6466 | 0.6079 |
Mar 3, 2023 | 0.6156 | 0.0290 | 4.94% | 0.5866 | 0.6258 | 0.5865 |
Angion Biomedica Corp. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 2.301 | 28.312 | 2.88 | 1.487 | 4.029 |
Ingresos | 2.301 | 28.312 | 2.88 | 1.487 | 4.029 |
Coste de los ingresos, total | 0 | 0.433 | 1.19 | 0.64 | 0.378 |
Beneficio bruto | 2.301 | 27.879 | 1.69 | 0.847 | 3.651 |
Gastos totales de explotación | 41.922 | 66.714 | 58.153 | 40.078 | 18.371 |
Gastos de venta/general/administración Gastos, total | 14.637 | 18.488 | 17.986 | 9.601 | 5.391 |
Investigación y desarrollo | 18.1 | 48.698 | 38.977 | 29.837 | 12.602 |
Ingresos de explotación | -39.621 | -38.402 | -55.273 | -38.591 | -14.342 |
Ingresos por intereses (gastos), netos No operativos | 0.719 | -2.191 | -8.249 | 0.488 | 0.401 |
Otros, netos | 0.095 | -13.98 | -16.527 | -2.555 | -6.084 |
Ingresos netos antes de impuestos | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
Ingresos netos después de impuestos | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
Beneficio neto antes de partidas extra. Elementos | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
Ingresos netos | -38.807 | -54.573 | -80.107 | -40.658 | -20.025 |
Total Adjustments to Net Income | 0 | -4.98 | |||
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
Beneficio neto diluido | -38.807 | -54.573 | -80.107 | -40.658 | -25.005 |
Promedio ponderado de acciones diluidas | 30.0407 | 28.2448 | 14.7621 | 9.97635 | 9.97635 |
BPA diluido sin partidas extraordinarias | -1.29181 | -1.93214 | -5.42652 | -4.07544 | -2.50643 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
BPA normalizado diluido | -0.98606 | -1.96418 | -5.4226 | -4.07544 | -2.50643 |
Gain (Loss) on Sale of Assets | 0 | -0.058 | |||
Gastos (ingresos) extraordinarios | 9.185 | -0.905 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0.653 | 1.648 | 25.941 |
Ingresos | 0 | 0 | 0.653 | 1.648 | 25.941 |
Coste de los ingresos, total | 0.433 | ||||
Beneficio bruto | 25.508 | ||||
Gastos totales de explotación | 7.051 | 9.05 | 9.688 | 16.133 | 11.307 |
Gastos de venta/general/administración Gastos, total | 3.745 | 3.315 | 3.615 | 4.466 | 4.206 |
Investigación y desarrollo | 0.16 | 2.938 | 6.073 | 11.667 | 6.668 |
Ingresos de explotación | -7.051 | -9.05 | -9.035 | -14.485 | 14.634 |
Ingresos por intereses (gastos), netos No operativos | 0.606 | 0.053 | -0.146 | 0.206 | -0.016 |
Otros, netos | 0.005 | 0.009 | 0.042 | 0.039 | 0.272 |
Ingresos netos antes de impuestos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Ingresos netos después de impuestos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Beneficio neto antes de partidas extra. Elementos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Ingresos netos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Beneficio neto diluido | -6.44 | -8.988 | -9.139 | -14.24 | 14.89 |
Promedio ponderado de acciones diluidas | 30.1146 | 30.1134 | 29.9739 | 29.9592 | 29.9654 |
BPA diluido sin partidas extraordinarias | -0.21385 | -0.29847 | -0.3049 | -0.47531 | 0.49691 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -0.10938 | -0.20559 | -0.3049 | -0.47531 | 0.49691 |
Gastos (ingresos) extraordinarios | 3.146 | 2.797 | 0 | 0 | |
Gain (Loss) on Sale of Assets | 0 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Total Activo Corriente | 91.247 | 42.297 | 6.106 | 25.679 |
Efectivo e inversiones a corto plazo | 88.756 | 34.607 | 5.571 | 25.512 |
Efectivo y Equivalentes | 88.756 | 34.607 | 5.571 | 25.512 |
Total deudores, neto | 0.806 | 5 | 0.44 | 0.107 |
Prepaid Expenses | 1.031 | 0.352 | 0.095 | 0.06 |
Total Assets | 96.513 | 47.347 | 11.886 | 26.628 |
Property/Plant/Equipment, Total - Net | 4.437 | 4.228 | 4.781 | 0.017 |
Property/Plant/Equipment, Total - Gross | 4.954 | 4.654 | 5.109 | 0.295 |
Accumulated Depreciation, Total | -0.517 | -0.426 | -0.328 | -0.278 |
Long Term Investments | 0.723 | 0.822 | 0.999 | 0.932 |
Total Current Liabilities | 11.296 | 107.449 | 26.575 | 7.355 |
Accounts Payable | 4.71 | 5.578 | 11.239 | 0.534 |
Accrued Expenses | 4.113 | 7.276 | 3.694 | 2.98 |
Notes Payable/Short Term Debt | 0 | 51.43 | 5.848 | 0 |
Other Current Liabilities, Total | 2.415 | 43.165 | 5.794 | 3.841 |
Total Liabilities | 15.006 | 137.796 | 30.472 | 7.717 |
Total Long Term Debt | 0.235 | 0.635 | 0 | 0 |
Other Liabilities, Total | 3.475 | 29.712 | 3.897 | 0.362 |
Total Equity | 81.507 | -90.449 | -18.586 | 18.911 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
Common Stock | 0.3 | 0.156 | 0.095 | 0.094 |
Additional Paid-In Capital | 296.445 | 72.136 | 63.584 | 60.138 |
Retained Earnings (Accumulated Deficit) | -215.135 | -160.562 | -80.455 | -39.797 |
Treasury Stock - Common | 0 | -1.846 | -1.81 | -1.524 |
Total Liabilities & Shareholders’ Equity | 96.513 | 47.347 | 11.886 | 26.628 |
Total Common Shares Outstanding | 29.9591 | 15.3167 | 9.97635 | 9.97635 |
Other Current Assets, Total | 0.654 | 2.338 | ||
Long Term Debt | 0 | 0.635 | ||
Other Equity, Total | -0.103 | -0.333 | ||
Other Long Term Assets, Total | 0.106 | |||
Current Port. of LT Debt/Capital Leases | 0.058 | |||
Capital Lease Obligations | 0.235 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 76.239 | 91.247 | 104.393 | 119.702 | 133.498 |
Efectivo e inversiones a corto plazo | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
Efectivo y Equivalentes | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
Total deudores, neto | 0 | 0.806 | 0 | 0 | 0 |
Prepaid Expenses | 0.021 | 1.031 | 1.018 | 1.761 | 2.343 |
Other Current Assets, Total | 3.216 | 0.654 | 0.639 | 0.628 | 0.699 |
Total Assets | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
Property/Plant/Equipment, Total - Net | 4.209 | 4.437 | 4.652 | 4.776 | 4.787 |
Property/Plant/Equipment, Total - Gross | 4.758 | 4.954 | 5.137 | 5.231 | 5.219 |
Accumulated Depreciation, Total | -0.549 | -0.517 | -0.485 | -0.455 | -0.432 |
Long Term Investments | 0.732 | 0.723 | 0.862 | 0.843 | 0.877 |
Other Long Term Assets, Total | 0.078 | 0.106 | 0.033 | 0.038 | 0.038 |
Total Current Liabilities | 10.381 | 11.296 | 17.946 | 20.524 | 16.963 |
Accounts Payable | 3.433 | 4.71 | 7.679 | 9.307 | 6.69 |
Accrued Expenses | 6.16 | 4.113 | 6.219 | 5.522 | 4.872 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.895 |
Other Current Liabilities, Total | 0.728 | 2.415 | 4.048 | 5.695 | 4.506 |
Total Liabilities | 14.056 | 15.006 | 45.426 | 48.17 | 46.757 |
Total Long Term Debt | 0.219 | 0.235 | 0 | 0 | 0 |
Long Term Debt | 0 | 0 | 0 | 0 | |
Other Liabilities, Total | 3.456 | 3.475 | 27.48 | 27.646 | 29.794 |
Total Equity | 67.202 | 81.507 | 64.514 | 77.189 | 92.443 |
Common Stock | 0.3 | 0.3 | 0.304 | 0.303 | 0.3 |
Additional Paid-In Capital | 296.476 | 296.445 | 298.518 | 295.636 | 292.67 |
Retained Earnings (Accumulated Deficit) | -229.375 | -215.135 | -230.025 | -214.321 | -197.249 |
Treasury Stock - Common | 0 | -4.21 | -4.21 | -2.991 | |
Other Equity, Total | -0.199 | -0.103 | -0.073 | -0.219 | -0.287 |
Total Liabilities & Shareholders’ Equity | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
Total Common Shares Outstanding | 29.9594 | 29.9591 | 29.9331 | 29.7976 | 29.6605 |
Current Port. of LT Debt/Capital Leases | 0.06 | 0.058 | |||
Capital Lease Obligations | 0.219 | 0.235 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Ingresos netos/Línea de salida | -54.573 | -80.107 | -40.658 | -20.025 |
Efectivo de actividades de explotación | -52.643 | -22.888 | -24.589 | -8.02 |
Efectivo de actividades de explotación | 0.091 | 0.098 | 0.05 | 0.002 |
Partidas no monetarias | 27.809 | 31.352 | 6.269 | 9.051 |
Cash Taxes Paid | 0 | 0 | ||
Intereses pagados en efectivo | 0.007 | 0 | 0 | |
Cambios en el capital circulante | -25.97 | 25.769 | 9.75 | 2.952 |
Efectivo de actividades de inversión | -0.382 | -0.041 | -0.242 | 0 |
Gastos de capital | -0.382 | -0.041 | -0.242 | 0 |
Efectivo procedente de actividades de financiación | 107.171 | 52.409 | 4.89 | 31.741 |
Emisión (retiro) de acciones, neto | -0.617 | 20.813 | -0.375 | 28.596 |
Emisión (amortización) de deuda, neta | 0.293 | 32.118 | 5.265 | 3.145 |
Variación neta de la tesorería | 54.149 | 29.036 | -19.941 | 23.721 |
Elementos de flujo de caja de financiación | 107.495 | -0.522 | ||
Efectos del cambio de divisas | 0.003 | -0.444 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.24 | -54.573 | -69.463 | -53.759 | -36.687 |
Cash From Operating Activities | -15.653 | -52.643 | -38.281 | -23.082 | -12.551 |
Cash From Operating Activities | 0.032 | 0.091 | 0.059 | 0.029 | 0.006 |
Non-Cash Items | 0.179 | 27.809 | 25.729 | 23.505 | 21.675 |
Changes in Working Capital | -1.624 | -25.97 | 5.394 | 7.143 | 2.455 |
Cash From Investing Activities | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
Capital Expenditures | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
Cash From Financing Activities | -0.014 | 107.171 | 106.767 | 106.068 | 108.444 |
Financing Cash Flow Items | 0 | 107.495 | -5.52 | -5.428 | -2.797 |
Issuance (Retirement) of Stock, Net | 0 | -0.617 | 112.287 | 111.496 | 111.241 |
Issuance (Retirement) of Debt, Net | -0.014 | 0.293 | 0 | 0 | 0 |
Foreign Exchange Effects | -0.087 | 0.003 | -0.011 | 0.005 | -0.003 |
Net Change in Cash | -15.754 | 54.149 | 68.129 | 82.706 | 95.849 |
Cash Interest Paid | 0.007 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Satterfield (Thomas A Jr) | Individual Investor | 7.2983 | 2197825 | 623278 | 2022-12-31 | LOW |
Vifor (International), Ltd | Corporation | 6.6269 | 1995643 | 0 | 2023-03-15 | LOW |
EISA-ABC LLC | Corporation | 5.719 | 1722237 | 0 | 2023-03-15 | LOW |
Goldberg (Itzhak D) | Individual Investor | 5.6193 | 1692199 | 4213 | 2023-03-15 | LOW |
Venkatesan (Jay R) | Individual Investor | 3.9765 | 1197498 | 0 | 2023-03-15 | LOW |
BVF Partners L.P. | Hedge Fund | 3.5574 | 1071297 | 0 | 2022-12-31 | LOW |
Nantahala Capital Management, LLC | Hedge Fund | 3.4308 | 1033145 | -32867 | 2022-12-31 | MED |
Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2023-03-15 | LOW |
CM Management, LLC | Investment Advisor | 2.4313 | 732178 | 132178 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1386 | 644035 | 675 | 2022-12-31 | LOW |
Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 0 | 2022-12-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5593 | 168436 | -451 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4041 | 121700 | -87277 | 2022-12-31 | HIGH |
Omenn (Gilbert S) | Individual Investor | 0.2667 | 80326 | 0 | 2023-03-15 | LOW |
Millennium Management LLC | Hedge Fund | 0.2502 | 75342 | -50261 | 2022-12-31 | HIGH |
Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-12-31 | LOW |
Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
Ergoteles Capital | Hedge Fund | 0.1757 | 52913 | -25944 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1696 | 51069 | 1188 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
Sobre Angion Biomedica Corp
Angion Biomedica Corp. es una empresa biofarmacéutica en fase avanzada. La empresa se centra en el descubrimiento, el desarrollo y la comercialización de pequeñas moléculas terapéuticas para tratar las lesiones agudas de órganos y las enfermedades fibróticas. El principal producto candidato de la empresa es ANG-3777. Su cartera de productos incluye ANG-3070, rho quinasa 2 (ROCK2) y CYP11B2. Su ANG-3777 es un mimético del factor de crecimiento de los hepatocitos (HGF) que está evaluando en múltiples lesiones agudas de órganos e indicaciones relacionadas, incluida la lesión renal aguda (LRA) y las lesiones de otros órganos, como los pulmones, el sistema nervioso central (SNC) y el corazón. También está evaluando el ANG-3777 para indicaciones dentro de las lesiones pulmonares agudas (LPA), centrándose en el síndrome de dificultad respiratoria aguda (SDRA), así como en las lesiones agudas del SNC. Los otros programas de la empresa son para el tratamiento de enfermedades fibróticas, ANG-3070, un inhibidor de la tirosina quinasa (TKI), e inhibidor de la rho quinasa 2 (ROCK2).
Industry: | Biotechnology & Medical Research (NEC) |
7-57 Wells Avenue
NEWTON
MASSACHUSETTS 02459
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com